Gene-Editing Startups Downplay Potential of Cancer Side Effect
(Bloomberg) -- Medical researchers say two new studies suggest that a cutting-edge therapy to repair defective genes could promote cancer-causing mutations in cells, a possible safety concern that some of the hottest companies in biotechnology may have to account for as they start human trials.
The laboratory studies were published Monday in the journal Nature Medicine. They suggest that, under the right conditions, the gene-editing method called CRISPR-Cas9 might promote mutations in a gene that's also defective in many malignant cells.
Cells with mutations in the gene, called p53, can't properly stop cells with DNA damage from dividing so the damage can be repaired -- which can be a key driver of cancer.
On Monday, the stocks of three companies developing the therapies plunged, as investors weighed whether the news would slow the introduction of treatments based on the technology. Crispr Therapeutics AG fell 13 percent at the close, while Editas Medicine Inc. dropped 7.8 percent and Intellia Therapeutics Inc. fell 9.8 percent.
Matthew Harrison, an analyst with Morgan Stanley, called the concerns overblown.
“Theoretical concerns will continue to arise with regards to gene editing until the first substantial set of clinical data is generated given the interest and volume of preclinical work being conducted in the field, but do not see any direct concerns,” he said in a note to clients. He has an equal-weight rating on Editas.
Companies Respond
The three gene editing companies said they did not believe the potential p53 risk would affect their programs.
“We do not believe the theoretical risks described in these papers apply to Crispr Therapeutics' programs,” company spokesman Christopher Erdman said in a statement. He said the company is using what are known as gene disruption and high-efficiency gene-correction methods, different than the ones used in the Nature Medicine studies.
Intellia “has not found this type of effect” in any of its animal or laboratory studies “despite extended observation,” Jennifer Mound Smoter, a spokeswoman for the company, said in an email. Intellia's current work is focused on different cell types than the ones used in the Nature Medicine studies.
Editas Medicine can achieve “much higher targeted integration rates and gene correction without suppressing p53 than the authors of this paper saw in their experiment,” Cristi Barnett, a spokeswoman for the company, said in an email.
Jussi Taipale, a cancer researcher at the University of Cambridge who is a senior author on one of the two studies, said that gene-editing research should “move forward cautiously” to look for any evidence that the methods the companies are using could be selecting for cancer-promoting traits.
“I would think the risk is relatively minor, but it would still be important to build in safeguards into studies,” Taipale said. The study was done in conjunction with researchers at the Karolinska Institutet in Sweden.
The second Nature Medicine study is from scientists at Novartis AG who were investigating why it's harder to edit the genes in another type of cell, human pluripotent stem cells. They found that the cells die off after certain types of gene editing, triggered by functioning p53.
As a consequence, the process could leave more surviving cells with mutations, the Novartis researchers said in the study.
--With assistance from Tatiana Darie.
To contact the reporters on this story: Robert Langreth in New York at rlangreth@bloomberg.net;Bailey Lipschultz in New York at blipschultz@bloomberg.net
To contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy Annett
©2018 Bloomberg L.P.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.